Skip to main content
. 2008 Jul 22;99(3):392–397. doi: 10.1038/sj.bjc.6604483

Table 2. Examples of clinically used tumour-targeted nanomedicines.

Compound Name Indication Status
Liposomal doxorubicin Myocet, Caelyx (Doxil) Breast, ovarian, KS Approved
Liposomal daunorubicin Daunoxome Kaposi sarcoma Approved
Liposomal vincristine Onco-TCS Non-hodgkin lymphoma Approved
Liposomal cisplatin SPI-77 Lung Phase II
Liposomal lurtotecan OSI-221 Ovarian Phase II
Cationic liposomal c-Raf AON LErafAON Various Phase I/II
Cationic liposomal E1A pDNA PLD-E1A Breast, ovarian Phase I/II
Thermosensitive liposomal doxorubicin ThermoDox Breast, liver Phase I
       
Albumin-paclitaxel Abraxane Breast Approved
Albumin-methotrexate MTX-HSA Kidney Phase II
Dextran-doxorubicin DOX-OXD Various Phase I
PEG-L-asparaginase Oncaspar Leukaemia Approved
PEG-IFNα2a/−IFNα2b PegAsys/PegIntron Melanoma, leukaemia Phase I/II
PHPMA-doxorubicin PK1 Breast, lung, colon Phase II
Galactosamine-targeted PK1 PK2 Liver Phase I/II
PGA-paclitaxel Xyotax Lung, ovarian Phase III
       
Paclitaxel-containing polymeric micelles Genexol-PM Breast, lung Phase II
Cisplatin-containing polymeric micelles Nanoplatin Various Phase I
Doxorubicin-containing polymeric micelles NK911 Various Phase I
SN38-containing polymeric micelles LE-SN38 Colon, colorectal Phase I
       
90Yttrium-Ibritumomab tiuxetan (α-CD20) Zevalin Non-hodgkin lymphoma Approved
DTA-IL2 fusion protein (α-CD25) Ontak T-cell lymphoma Approved
Ozogamycin-gemtuzumab (α-CD33) Mylotarg Leukaemia Approved
Doxorubicin-cBR96 (α-CD174) SGN-15 Lung, prostate, breast Phase II